欢迎访问中国中西医结合杂志！

目的：探讨复方丹参滴丸对冠心病不稳定性心绞痛（UAP）患者血浆α颗粒膜蛋白-140（GMP－140）的影响及临床疗效。方法：42例不稳定性心绞痛患者随机分为复方丹参滴丸组（简称丹参组）和对照组，两组同时服用阿司匹林等药物，治疗4周，丹参组还予复方丹参滴丸，每次10粒，每天3次，治疗前后采用ELISSA法检测血浆GMP-140水平，并观察心绞痛症状、心电图缺血变化。同时选择22名门诊健康体检者为健康人组。结果：治疗前丹参组、对照组血浆GMP－140水平明显高于健康人组（P＜0．01）；治疗后丹参组心绞痛症状、心电图缺血较对照组明显改善，同时血浆GMP140水平较对照组显著下降（P＜0．05），与健康人组比较无显著性差异（P＞0．05），对照组血浆GMP－140水平仍高于健康人组（P＜0．05）。结论：复方丹参滴丸与阿司匹林联合应用可抑制UAP患者血小板活化功能的异常，并具良好的抗心绞痛临床疗效。

英文摘要:

Objective: To explore the effect of Composite Salviae Dropping Pill (CSDP) on the level of α-granule mem brane protein-140 (GMP-140) in unstable angina pectoris (UAP). Methods: Forty-two patients of UAP were randomly divided into the CSDP group and the control group, 21 cases in each group. The two groups were all received the treatment of aspirin and other conservative agents, and CSDP was given to the CSDP group orally, 10 pills three times a day for 4 weeks additionally. The GMP-140 level was determined by ELISA, changes of symptoms of angina, ECG were observed before and after treatment. Besides, 22 healthy persons were selected as the normal control. Results: The level of GMP-140 in the two treated groups was significantly higher than that in the normal control group before treatment (P< 0. 01). After 4 weeks’ treatment of CSDP, the symp toms of angina, ischemia feature in ECG improved in the CSDP group more apparently than those in the control group. Moreover, the GMP-140 level in the CSDP group was reduced significantly as compared with the control group, and to approach the level of normal (P>0. 05), while in the control group, it was higher as compared with the normal control (P<0. 05). Conclusion: CSDP combined with aspirin may inhibit platelet activation in UAP patients and showed good effect in ameliorating angina in clinical practice.

View Full Text View/Add Comment Download reader